Quest Diagnostics Inc (DGX)
Health Care · Health Care Services · US stock · S&P 500 component
$235.00
▼ -4.15 (1.74%)
Fair valueFair
$247 +5.1% to fair value
$123fair band $173–$321$370
Day's range
$233.56 – $240.75
52-week range
$168.35 – $247.92
About Quest Diagnostics Inc
Quest Diagnostics provides diagnostic testing and information services. It runs laboratories and patient service centers that perform routine and specialised tests for physicians, hospitals and employers, and it analyses results for health care organizations. The company earns money from payments by health insurers, government programs and patients for tests performed. Testing volumes, reimbursement rates and the efficiency of its laboratory network influence its results.
Sales came to $11.6 billion in the last twelve months, having expanded at 3.7% a year across the last three years. Its operating margin came to 14.1%, and return on invested capital was 10%. Net debt stands at 2.3 times EBITDA. The company pays a dividend, yielding 1.4%. On the site's X-Ray Score it receives 57 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $168.35 – $247.92Volume 799,540Daily, split-adjusted
Vitals
Market cap$26.3B
52-week range$168.35 – $247.92
Volume (last day)799,540
P/E (TTM)24.9
EBIT / EV yield5.2%
Free-cash-flow yield5.1%
Dividend yield1.4%
Revenue (TTM)$11.6B
Net income (TTM)$1.1B
Operating margin14.1%
Return on capital10.0%
Debt incl. leases$5.6B
Cash & securities$626M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$247model spread $235 – $259
Fair
+5.1% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $235
Undervalued < $173Fair $173 – $321Overvalued > $321
10-year DCF (market-scaled)
$192
Peer multiples
$263
Earnings power floor (not blended)
$105
Fundamentals-adjusted multiple
$285
Growth the price implies
12.5%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
63/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield5.2%
Free-cash-flow yield5.1%
Fair value vs price1.1×
Growth
Fair
55/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)3.7%
EPS growth (3y)3.2%
Growth consistency100%
Profitability
Weak
45/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital10.0%
Operating margin14.1%
Gross profitability22.6%
Financial health
Fair
68/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA2.3×
Interest coverNo interest cost
Dividends
Fair
55/100
Dividend is typical for its sector.
See the numbers →
Dividend yield1.4%
Dividends vs free cash flow28%
Dividend growth5.0%
Quarterly results: last 6 quarters
+12.1%
Mar '25
+15.2%
Jun '25
+13.2%
Sep '25
+7.1%
Dec '25
+9.2%
Mar '26
+10.2%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $3.0B, diluted EPS $2.84.
Compare with peers
DVA Davita Inc.66 CI Cigna Group66 CVS CVS HEALTH Corp52 LH Labcorp Holdings Inc.46Other Health Care Services companies by X-Ray Score.
Fundamentals checklist
● 5 Good · ● 10 Average · ● 1 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldAverage
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Average
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioAverage
Net debt / EBITDAAverage
Interest coverGood
Valuation
Fair value vs priceAverage
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginAverage
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 55/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $10.8B | $9.9B | $9.3B | $9.9B | $11.0B |
| Operating income | $2.4B | $1.4B | $1.3B | $1.3B | $1.6B |
| Net income | $2.0B | $946M | $854M | $871M | $992M |
| Operating cash flow | $2.2B | $1.7B | $1.3B | $1.3B | $1.9B |
| Operating margin | 22.1% | 14.4% | 13.6% | 13.6% | 14.1% |
| Free cash flow | $1.8B | $1.3B | $864M | $909M | $1.4B |
| Diluted EPS | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
10 bullish · 4 neutral · 2 bearish
Weekly
Strongly bullish
10 bullish · 1 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 231.9 | Bullish |
| EMA 10 | 233.5 | Bullish |
| SMA 20 | 233.2 | Bullish |
| EMA 20 | 233.8 | Bullish |
| SMA 50 | 236.7 | Bearish |
| EMA 50 | 232.3 | Bullish |
| SMA 100 | 222.8 | Bullish |
| EMA 100 | 224.4 | Bullish |
| SMA 200 | 207.3 | Bullish |
| EMA 200 | 211.4 | Bullish |
Oscillators (daily)
| RSI (14) | 51.38 | Neutral |
| MACD (12, 26) | -0.59 | Bearish |
| Momentum (12) | 1.20 | Bullish |
| Stochastic %K (14) | 61.59 | Neutral |
| Williams %R (14) | -38.41 | Neutral |
| CCI (20) | 79.85 | Neutral |
Pivot points (classic, last session)
S3 224.9 | S2 229.2 | S1 232.1 | Pivot 236.4 | R1 239.3 | R2 243.6 | R3 246.5 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
3.38 USD
Yield on today's price
1.44%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 6 Oct 2026 | 0.8600 |
| 8 Jul 2026 | 0.8600 |
| 6 Apr 2026 | 0.8600 |
| 13 Jan 2026 | 0.8000 |
| 3 Oct 2025 | 0.8000 |
| 7 Jul 2025 | 0.8000 |
| 7 Apr 2025 | 0.8000 |
| 14 Jan 2025 | 0.7500 |
| 4 Oct 2024 | 0.7500 |
| 8 Jul 2024 | 0.7500 |
| 5 Apr 2024 | 0.7500 |
| 16 Jan 2024 | 0.7100 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
DGX SEC filings
6 Oct 2026
8-KSEC EDGAR
Director or officer change
23 Jul 2026
10-QSEC EDGAR
Quarterly report
23 Jul 2026
8-KSEC EDGAR
Results of operations
21 May 2026
8-KSEC EDGAR
Shareholder vote results
8 May 2026
8-KSEC EDGAR
Entered a material agreement
1 May 2026
8-KSEC EDGAR
Other events
22 Apr 2026
10-QSEC EDGAR
Quarterly report
21 Apr 2026
8-KSEC EDGAR
Results of operations
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.